ANI Pharmaceuticals makes an offer to acquire Egetis Therapeutics, as Egetis separately agrees to sell its priority review voucher for $190 million.
Feature|Articles|September 30, 2026
Life Sciences Compliance: Diagnosis Incomplete
Author(s)Avi Pardo
Life sciences spends billions on compliance — but WhatsApp, iMessage, and SMS conversations between field teams and HCPs remain invisible to oversight.
Advertisement
Advertisement
Life sciences companies operate under some of the most exacting regulatory scrutiny of any industry. From drug development and clinical trials to promotional practices and HCP engagement, pharmaceutical, biotechnology and medical device companies invest enormous resources in compliance: building policies, training employees, monitoring marketing claims and documenting every interaction that touches a regulated process.
Related to this article
FDA has approved Merck KGaA’s Pimjetmi, an oral CSF-1R inhibitor, for adults with symptomatic tenosynovial giant cell tumors.
FDA approves Bayer’s asundexian as the first Factor XIa inhibitor for secondary stroke prevention, the FDA requires a new safety label warning across all GLP-1 receptor agonists for a potential NAION risk, and AstraZeneca acquires Omniose to add a bioconjugation platform to its vaccine pipeline.
AstraZeneca acquires Omniose, to bolster it's preclinical infectious disease programs.
FDA is requiring manufacturers of all GLP-1 receptor agonists to add a warning for a potential increased risk of NAION.
FDA approves Bayer’s asundexian (Sunharbo), the first Factor XIa inhibitor, for secondary stroke prevention.
argenx acquires Unnatural Products, adding a macrocyclic peptide discovery platform to complement its antibody engineering.
Hims & Hers partners with Eli Lilly to sell Zepbound and Foundayo directly on its platform, Novo Nordisk terminates its research collaboration with Korro Bio, and the FDA grants accelerated approval to Johnson & Johnson’s Rybrevant Faspro in head and neck cancer.
Advertisement
Advertisement